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Abstract
SH2B adaptor protein family members (SH2B1-3) regulate various physiological responses through affecting signaling, gene
expression, and cell adhesion. SH2B1 and SH2B2 were reported to enhance nerve growth factor (NGF)-induced neuronal
differentiation in PC12 cells, a well-established neuronal model system. In contrast, SH2B3 was reported to inhibit cell
proliferation during the development of immune system. No study so far addresses the role of SH2B3 in the nervous system. In
this study, we provide evidence suggesting that SH2B3 is expressed in the cortex of embryonic rat brain. Overexpression of
SH2B3 not only inhibits NGF-induced differentiation of PC12 cells but also reduces neurite outgrowth of primary cortical
neurons. SH2B3does sobyrepressing NGF-induced activationof PLCc, MEK-ERK1/2and PI3K-AKTpathwaysand the expression
of Egr-1. SH2B3 is capable of binding to phosphorylated NGF receptor, TrkA, as well as SH2B1b. Our data further demonstrate
that overexpression of SH2B3 reduces the interaction between SH2B1b and TrkA. Consistent with this finding, overexpressing
the SH2 domain of SH2B3 is sufficient to inhibit NGF-induced neurite outgrowth. Together, our data demonstrate that SH2B3,
unlike the other two family members, inhibits neuronal differentiation of PC12 cells and primary cortical neurons. Its inhibitory
mechanism is likely through the competition of TrkA binding with the positive-acting SH2B1 and SH2B2.
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Introduction
SH2B protein family members, including SH2B1 (SH2-B, PSM),
SH2B2 (APS), and SH2B3 (Lnk), are adaptor proteins that regulate
several signaling pathways. These family members contain dimeriza-
tion domain, proline-rich regions, pleckstrin homology (PH), and src
homology 2 (SH2) domains. SH2B family members participate in
various physiological responses and developmental processes. For
metabolic control, SH2B1 and SH2B2 interact with insulin receptor
substrate 1 (IRS1), IRS2, or Janus kinase 2 (JAK2) to regulate insulin,
leptin, and growth hormone signaling [1,2,3,4,5,6]. SH2B1 null mice
are obese and develop diabetes [6,7]. SH2B1 and SH2B2 have also
been implicated in neuronal differentiation in PC12 cells and the
development of sympathetic neurons [8,9]. In PC12 cells, nerve
growth factor (NGF) binds to the receptor TrkA and activates
downstream effectors, such as Shc, phospholipase C gamma (PLCc,
Protein kinase C (PKC), phosphatidylinositol 3-kinases (PI3K)-AKT
and the Ras-related mitogen activated protein kinase (MAPK)
pathways [10]. The formation of homo- or heterodimers by SH2B1
and SH2B2 through dimerization domain is required for the
activation of TrkA [11]. By binding to activated TrkA through its
SH2 domain, SH2B1b prolongs TrkA signaling [9]. For cortical
neuron development and survival, brain-derived neurotrophic factor
(BDNF)-induced PI3K-AKT signaling pathway is required
[12,13,14]. SH2B1 and SH2B2 are phosphorylated in response to
BDNF in cortical neurons [8].
SH2B2 and SH2B3, on the other hand, are known as negative
regulators of B cell proliferation [15,16]. During the development
of hematopoietic stem cells, SH2B3 interacts with JAK2 and
myeloproliferate leukemia virus oncogene (Mpl) to decrease
thrombopoietin-mediated self-renewal [17] through inhibiting
signaling pathways including PI3K-AKT, signal transducer and
activator of transcription 5 (STAT5), and enhancing p38 MAPK
[18]. During stem cell factor (SCF)-mediated mast cell develop-
ment, SH2B3 serves as a negative regulator which interacts with c-
Kit receptor then inhibits downstream ERK1/2 signaling [19]. In
tumor necrosis factor-a (TNFa)-mediated inflammatory response
of endothelial cells, overexpressing SH2B3 inhibits pERK1/2 and
then down-regulates the expression of VCAM-1[20]. Despite the
similarity in the domain structure of SH2B3 and other family
members, these reports suggest that SH2B3 generally acts as a
negative regulator for signaling control. Although a previous study
reported that SH2B3 expressed in the brain [21], its role in the
brain has not been addressed. In this study, we investigated the
role of SH2B3 in neurotrophic factor signaling and neurite
outgrowth.
Materials and Methods
Animal Handling- Ethics statement
All experiments were conducted in accordance with the
guidelines of the Laboratory Animal Center of National Tsing
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26433Hua University (NTHU). Animal use protocols were reviewed and
approved by the NTHU Institutional Animal Care and Use
Committee (Approval number 09837).
Reagents
2.5 S mouse Nerve growth factor and rat tail collagen I were
purchased from BD Bioscience (Franklin Lakes, NJ). Human
fibroblast growth factor 1 was purchased from Chingen Inc.
(Dublin, OH) and heparin was purchased from Sigma. Protein A
sepharose beads was purchased from GE Healthcare bioscience
(Piscataway, NJ). Protein G agarose beads, goat anti-SH2B3,
rabbit anti-Egr-1, rabbit anti-Tau-1, and rabbit anti-TrkA
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). TRIzol reagent, Lipofectamine 2000, Alexa Flour 700
goat anti-mouse IgG, and Alexa Fluor 555-conjugated goat anti-
mouse IgG secondary antibodies were purchased from Invitrogen
(Carlsbad, CA). Profection mammalian transfection system was
purchased from Promega (Madison, WI). Rabbit anti-GFP and
mouse anti-myc tag antibodies were purchased from Hopegen
Biotechnology Development Enterprise (Taipei, Taiwan). Rabbit
anti-ERK1/2 antibody and rabbit anti-goat horseradish peroxi-
dase (HRP)-conjugated IgG were purchased from Sigma-Aldrich
(St. Louis, MO). Rabbit anti-Akt, mouse anti-STAT3, mouse anti-
pERK1/2, mouse anti-phospho-Akt Ser473, rabbit anti-PLCc,
rabbit anti-phospho-PLCc, and rabbit anti-phospho-STAT3
Ser727 antibodies were purchased from Cell Signaling (Danvers,
MA). Rabbit anti-phospho-TrkA Tyr490 antibody was purchased
from GeneTex (Irvine, CA).
Cell lines and cell culture
PC12 and 293T cells were purchased from American Type
Culture Collection. PC12 cells were maintained in DMEM
containing 10% horse serum (HS), 5% fetal bovine serum (FBS),
1% L-glutamine (L-Gln), 1% antibiotic-antimycotic (AA), and
cultured under 10% CO2 condition. 293T cells were grown in
DMEM containing 10% FBS, 1% L-Gln, 1% AA, and under 5%
CO2 condition. PC12 cells stably overexpressing GFP (PC12-GFP
cells) or GFP-SH2B1b (PC12-SH2B1b cells) were made according
to Chen et al [22]. PC12 cells stably overexpressing GFP-SH2B3
(PC12-SH2B3 cells) were made by transfecting GFP-SH2B3 to
PC12 cells and selecting with medium containing 5 mg/ml of
G418 (Invitrogen) for at least 30 days. Pooled populations of stable
clones were used to avoid clonal variation.
Plasmids
pEGFP-C1, pRK5-myc, pEGFP-SH2B1b, myc-SH2B1b and
myc-SH2B1b(R555E) were generous gifts from Dr. Christin
Carter-Su at University of Michigan, USA [9,23]. Wild type and
R392E mutant of human SH2B3 constructs (in pcDNA3.1) were
provided by Dr. Sigal Gery at University of California, Los
Angeles School of Medicine, USA [24]. Full length and R392E
mutant of SH2B3 were both sub-cloned into pRK5-myc via
BamHI/XbaI sites. Full length, R392E mutant, N-terminal region
(amino acids 1-296), and C-terminal region of SH2B3 (amino
acids 296–575) were also sub-cloned into pEGFP-C1 via BamHI/
XbaI, HindIII/XbaI, BamHI/EcoRI, and EcoRI sites respective-
ly. pCMV5-TrkA was purchased from Addgene Inc. (Addgene
plasmid 15002).
Neuronal differentiation and microscopy
PC12 cells were plated on 35-mm culture dishes coated with
0.1 mg/ml of collagen I. For neuronal differentiation, NGF was
treated with 50 ng/ml or 100 ng/ml in low-serum medium
(DMEM containing 2% FBS, 1% HS, 1% L-Gln, and 1% AA).
For FGF1-idncued neuronal differentiation, FGF1 (100 ng/ml)
and heparin (10 mg/ml) were mixed in low-serum medium before
adding to cells as described in Lin [22]. The definition of
morphological differentiation in PC12 cells is that the length of
neurites should be at least twice the diameter of the cell body.
Images were taken using Zeiss Observer Z1 microscope. Neurite
length was measured using Image J software.
Primary culture of cortical neurons
Brain cortex was dissected from embryonic day 18 (E18)
embryos of Sprague-Dawley rats (purchased from BioLASCO
Taiwan Co., Ltd.), and treated with papain (10 U/ml) to dissociate
cells. Dissociated cells were washed and re-suspended in minimal
essential medium (MEM) supplemented with 5% HS and 5% FBS.
Neurons were then plated onto dishes coated with 30 mg/ml of
poly-L-lysine, and cultured in neurobasal medium with B27
(containing additional 0.025 mM glutamate) on DIV (day in vitro)
1. On DIV 3, cells were treated with 5 mM cytosine 1-b-D-
arabinofuranoside to inhibit the growth of glial cells. GFP, GFP-
SH2B3, GFP-SH2B3(1-296), and GFP-SH2B3(296-575) were
transfected to neurons on DIV 4, and then medium was replaced
by half of the fresh neurobasal/B27 medium every two days.
Total RNA purification and semi-quantitative real-time
polymerase chain reaction (Q-PCR)
TRIzol reagent was used to isolate total RNA from PC12 cells
according to the manufacture’s instruction. For reverse transcrip-
tion, 2 mg of total RNA was converted to cDNA using reverse
transcription kit (Applied Biosystems). Q-PCR was performed
using SYBR green master mix and ABI Prism 7500 real time PCR
system (Applied Biosystems) with specific primers. SH2B3 primer
pairs are: forward primer: CTTTCCTTAGTGGCAGAGCC;
reverse primer: GACACCCAGAGACCAAGGAT. Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) primer pairs are:
forward primer: ATGACTCTACCCACGGCAAGTT; reverse
primer: TCCCATTCTCAGCCTTGACTGT. All Q-PCR re-
sults were normalized to the levels of GAPDH.
Knockdown of SH2B3 via RNA interference
pLKO.1 lentiviral vector that contains oligonucleotides (CC-
GGGACCGGACAGACATCATCTTTCTCGAGAAAGATGA-
TGTCTGTCCGGTCTTTTTG) targeting human SH2B3 se-
quence (GACCGGACAGACATCATCTTT), pLKO.1-shSH2B3
(Clone number TRCN0000116286), was obtained from National
Core Facility at the Institute of Molecular Biology, Genomic
Research Center, Academic Sinica, Taiwan. Lentivirus containing
pLKO.1-shSH2B3 was prepared from 293T cells co-transfected
with pLKO.1-shSH2B3, pCMVDR8.91, and pMD.G. Medium
containing lentivirus was harvested 24 and 48 h after transfection
and added into PC12 cells in the presence of polybrene (10 mg/ml).
PC12 cells werethen subjectedto puromycin (5 mg/ml) selection for
at least 2 days.
Immunofluorescence and immunohistochemistry
For PC12 cells immunofluorescence, cells were plated on 35-
mm culture dishes coated with collagen I. After indicated
treatment, cells were fixed by 4% of paraformaldehyde (PFA),
and permeabilized by 0.1% of Triton X-100. Cells were then
incubated in blocking solution containing 1% bovine serum
albumin, followed by the incubation of indicated antibodies and
mounted with Prolong Gold reagent (Invitrogen). Images were
taken using Zeiss Observer Z1 microscope. E18 rat embryo brains
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overnight for dehydration. Before embedding, rat brains were
incubated in 50% O.C.T. (optimal cutting temperature) com-
pound mixed with 30% sucrose/PBS at room temperature for
2 hours. Rat brains were immersed in 100% O.C.T. compound
and embedded with liquid nitrogen. The embedded tissues were
conserved in 280uC before section. Embedded tissues were
sectioned by cryostat microtome (MICROM HM550) under 220
to 230uC, each section was 10 mm thick and picked up on a glass
slide. The slides were air-dried by placing at room temperature in
ventilator and then preserved in 220uC. Immunocytochemistry
images of rat brain slices were taken using Zeiss LSM 510 confocal
microscope.
Immunoblotting and immunoprecipitation
Cells were treated as indicated and lysates were collected in
RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM
EGTA, 1% Triton X.100) containing protease inhibitors (1 mM
Na3VO4, 10 ng/ml leupeptin, 10 ng/ml aprotinin, 1 mM phe-
nylmethylsulfonyl fluoride, PMSF). Proteins were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and then immobilized to nitrocellulose membrane for
western blotting analysis using the indicated antibodies. The
immunoblots were detected using either IRDye-conjugated IgG
and the Odyssey Infrared Imaging System (LI-COR Biosciences,
Lincoln, NE) or HRP-conjugated IgG and ECL system. For
immunoprecipitation, cell lysates were incubated with the
indicated antibodies and then Protein A sepharose or Protein G
agarose beads. Beads were washed with pre-chilled lysis buffer and
then boiled in Laemmli sample buffer. The immunoprecipitated
proteins were analyzed by western blotting.
Statistics
Q-PCR, neuronal differentiation, and immunoblotting quanti-
fication results were expressed as mean 6 standard error and
performed Paired Student’s t-test. Significance (*) was defined as
P,0.05. Quantification results of neurite length were expressed as
mean 6 standard deviation and performed one-way ANOVA.
Significance (*) was defined as P,0.05.
Results
SH2B3 is expressed in rat brain cortex and is a NGF-
induced gene
To investigate the neuronal role of SH2B3, we set out to
determine whether SH2B3 is expressed in the central nervous
system. The presence of SH2B3 in brain slices from E18 rat
embryos was determined via immunofluorescence staining. As
revealed in Figure 1A, SH2B3 was robustly expressed in the
cerebral cortex of brain. To understand whether SH2B3
participates in the development of nervous system, we used
PC12 cells, a well-documented neuronal model system, to address
the roles of SH2B3 in neuronal differentiation. PC12 cells can be
differentiated into sympathetic-like neurons in the presence of
neurotrophic factors such as NGF and FGF1 [25,26]. Based on
our previous microarray data, the relative mRNA levels of SH2B3
was increased four-fold in response to 6 h of NGF stimulation
(Figure 1B). Q-PCR analysis was performed to confirm the
microarray data. The relative mRNA levels of SH2B3 were
increased as early as 2 h after NGF addition, peaked at 4 h,
remained high at 6 h and reduced to near basal level by 12 h
(Figure 1C). The NGF-induced SH2B3 protein levels were
obviously increased by 4 h of NGF treatment and continued to
increase to at least 12 h. Although mRNA levels of SH2B3 were
reduced by 12 h, the protein levels remained high. These results
suggest that NGF-induced SH2B3 proteins are quite stable and
may function not only during initiation phase but also during
neurite elongation.
Overexpressing SH2B3 inhibits and reducing SH2B3
increases NGF-induced differentiation of PC12 cells
In order to perform biochemical studies to determine the role of
SH2B3 during neuronal differentiation, three stable cell lines –
PC12 cells overexpressing GFP (PC12-GFP cells), GFP-SH2B1b
(PC12-SH2B1b cells) or GFP-SH2B3 (PC12-SH2B3 cells) were
established. The expressions of SH2B1b and SH2B3 were
confirmed using western blotting (Figure 2A). To determine their
effect on neuronal differentiation, PC12-GFP, PC12-SH2B1b and
PC12-SH2B3 cells were treated with or without NGF for 4 days.
Consistent with previous results, PC12-SH2B1b cells enhanced
neurite outgrowth compared to PC12-GFP cells. In contrast,
PC12-SH2B3 cells dramatically reduced neurite outgrowth
(Figure 2B). The percentage of morphological differentiation was
determined as described in the Materials and Methods. As shown
in Figure 2C, approximately 25% of PC12-GFP cells were
differentiated, whereas more than 65% of PC12-SH2B1b cells and
less than 5% of PC12-SH2B3 cells were differentiated in response
to 50 ng/ml NGF for 4 days. Level of SH2B3 was reduced via
RNA interference approach. Lentivirus that contain shSH2B3
were used to infect PC12 cells. Level of SH2B3 mRNA was
determined via Q-PCR. As shown in Figure 2D, shSH2B3
reduced mRNA of SH2B3 to 40%. Knocking down SH2B3
enhanced NGF-induced neuronal differentiation (Figure 2E).
These results demonstrated that overexpressing SH2B3 inhibited,
whereas reducing SH2B3 increased, NGF-induced neuronal
differentiation.
SH2B3 down-regulates NGF- and FGF1-induced signaling
Given that SH2B family members are signaling adaptors, the
effect of overexpressing SH2B3 on neurotrophic factor signaling
was investigated. NGF is known to activate pathways involving
PLCc, MEK-ERK1/2 and PI3K-AKT. Thus, neurotrophic
factors-induced phosphorylations of PLCc, ERK1/2 and AKT
were compared among PC12-GFP, PC12-SH2B1b and PC12-
SH2B3 cell lines. In response to NGF, pPLCc, pERK1/2 and
pAKT were induced within 2-5 min. The relative levels of pPLCc
were increased in PC12-SH2B1b cells and reduced in PC12-
SH2B3 cells compared to PC12-GFP cells. Phosphorylation of
ERK1/2 was not obviously different between PC12-GFP and
PC12-SH2B1b cells whereas pERK1/2 levels were reduced in
PC12-SH2B3 cells compared to PC12-GFP cells. Phosphorylation
of AKT was higher in PC12-SH2B1b and lower in PC12-SH2B3
cells compared to PC12-GFP cells (Figure 3A-B). Previous studies
suggest that STAT3 functions downstream of ERK1/2 during
NGF and FGF1 signaling [22,27]. However, NGF-induced
pSTAT3 levels were not obviously different among these three
stable cell lines (Figure 3A–B). The expression of a NGF-
responsive gene, Egr-1, was also determined. As shown in
Figure 3C, the expression of Egr-1 was induced within 1 h after
the addition of NGF. While overexpression of SH2B1b did not
affect the expression of Egr-1, overexpression of SH2B3 reduced it
(Figure 3C–D). These results demonstrate that overexpression of
SH2B3 represses NGF signaling including the activation of PLCc,
ERK1/2, AKT and the expression of Egr-1.
To determine whether SH2B3 inhibits neuronal differentiation
in neurotrophic factor-specific manner, its effects on FGF1-
induced neurite outgrowth and signaling were also addressed.
Developmental response to FGF1 in PC12 cells is slower than that
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subjected to FGF1 stimulation for 6 days. PC12-SH2B1b cells
clearly enhanced FGF1-induced neurite outgrowth compared to
PC12 and PC12-SH2B3 cells inhibited it (Figure 4A). Neurite
outgrowth of PC12-SH2B1b cells was obvious within 2 days of
FGF1 treatment whereas no neurite initiation was found for
PC12-SH2B3 cells even after 7 days (data not shown). The
percentages of differentiation for PC12 control, PC12-SH2B1b,
and PC12-SH2B3 cells were in average 4, 20, and 1% respectively
(Figure 4B). FGF1-induced pERK1/2 and expression of Egr-1
were enhanced in PC12-SH2B1b cells and reduced in PC12-
SH2B3 cells (Figure 4C–D). Together with the data from Figure 3,
these results suggest that overexpression of SH2B3 inhibits both
NGF- and FGF1-induced signaling and neurite outgrowth.
SH2B3 reduces the interaction between SH2B1b and
TrkA
We next determine whether SH2B3 affects the functions of
SH2B1b and TrkA. SH2B1b and SH2B2 can form homo- or
heteromultimers through the conserved dimerization domain (DD)
[28], and bind to TrkA through SH2 domain [9]. SH2B3 also
contains the conserved DD and SH2 domains. Thus, it is possible
that SH2B3 may form heteromultimers with SH2B1 and may
interact with TrkA via SH2 domain. To this end, GFP-SH2B3 was
co-expressed with either myc-SH2B1b or myc-SH2B1b(R555E) of
which SH2 domain was mutated and cannot interact with TrkA.
Protein-protein interaction was determined by co-immunoprecip-
itation experiments. As shown in Figure 5A, GFP-SH2B3 was co-
immunoprecipitated with both SH2B1b and SH2B1b(R555E).
This result suggests that SH2B3 is capable of interacting with
SH2B1b, likely through DD domain, whereas SH2 domain of
SH2B1b is not required for the interaction with SH2B3. Based on
the similarity of the SH2 domain between SH2B1b and SH2B3
(Figure 5B), we anticipate that SH2B3 would bind to TrkA. To
this end, vector control, myc-SH2B1b, myc-SH2B3, or myc-
SH2B3(R392E), together with TrkA construct, were co-transfect-
ed to 293T cells followed by NGF stimulation for 15 min.
SH2B1b and SH2B3 were immunoprecipitated via anti-myc
Figure 1. Expression of SH2B3 in the E18 rat brain cortex and in PC12 cells. (A) Brain slices of E18 rats were subjected to
immunofluorescence staining using anti-SH2B3 antibody followed by Alexa Fluor 555-conjugated secondary antibody (shown in red). Enlarged
panels from the square box area are shown in the middle column. Secondary antibody controls (without primary antibody) are shown in the panels
on the right column. DAPI staining in blue shows the localization of the nucleus. Images were taken using Zeiss LSM 510. Scale bar: 50 mm. (B)
Microarray results generated from rat affymetrix chips. Relative mRNA expressions of SH2B3 in PC12-GFP cells treated without (Ctrl) or with 100 ng/ml
NGF for 6 h are shown. (C) Relative mRNA expressions of SH2B3 in PC12 cells treated with NGF 50 ng/ml for the indicated time periods were analyzed
using Q-PCR. The relative SH2B3 levels were normalized to the levels of GADPH. *: P,0.05, paired Student t-test. (D) Protein lysates from PC12 cells
treated with NGF 50 ng/ml for indicated time period were immunoblotted using anti-SH2B3 and anti-tubulin antibodies. Tubulin levels were used as
loading controls.
doi:10.1371/journal.pone.0026433.g001
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complexes was 10% of that in SH2B1b-containing complexes
(Figure 5B). This result suggests that most of the overexpressed
SH2B3 may form homodimers by itself, heterodimers with
SH2B1, or in other protein complexes. No interaction between
SH2B3(R392E) and TrkA was detected. Interestingly, when
immunoprecipitated TrkA, the relative amount of SH2B3 in
TrkA-containing complexes was 88% of SH2B1b (Figure 5C).
Similarly, no interaction between TrkA and SH2B3(R392E) was
found. These results suggest that, although relatively low level of
overexpressed SH2B3 binds to TrkA, the relative amounts of
SH2B3 and SH2B1b in TrkA-containing complexes are compa-
rable.
Once NGF binds to TrkA receptor, TrkA dimerizes and its
cytoplasmic region is tyrosine phosphorylated. SH2B1b has been
shown to bind to activated TrkA and positively enhances tyrosine
phosphorylation of TrkA to prolong downstream signaling
pathway [8,9]. The fact that SH2B3 could bind to both SH2B1b
and TrkA suggests that SH2B3 would affect SH2B1b-mediated
NGF signaling and neurite outgrowth. To test this hypothesis,
combinations of TrkA, myc-SH2B1b and GFP-SH2B3 were
transfected to 293T cells followed by NGF stimulation. As
revealed in the lysate, phosphorylation of TrkA at tyrosine 490
[pTrkA(Y490)] was increased when TrkA and SH2B1b were
overexpressed. pTrkA(Y490) recruits another adaptor protein Shc
and the levels of TrkA(Y490) is positively correlates with SH2B1-
mediated NGF signaling [8]. In contrast, as SH2B3 was also co-
expressed together with TrkA and SH2B1b, the level of
pTrkA(Y490) was reduced (Figure 5D, lower panels). This results
suggest that overexpression of SH2B3 may affect TrkA activation,
possibly through sequestering away SH2B1b from TrkA or
competing for TrkA binding with SH2B1b. As predicted, the
interaction between TrkA and SH2B1b was significantly reduced
when SH2B3 was also co-expressed (Figure 5D, upper panels). To
further examine whether SH2B3 would functionally reduce
SH2B1b-enhanced neuronal differentiation, PC12-SH2B1b cells
were transiently transfected with SH2B3 and NGF-induced
neurite outgrowth was determined. As shown in Figure 5E,
neurite outgrowth in PC12-SH2B1b cells that transiently overex-
pressed myc-SH2B3 (white arrows) was inhibited compared to
non-transfected or vector-transfected cells. Quantified results
showed that overexpressing SH2B3 in PC12-SH2B1b cells
significantly inhibited neuronal differentiation (Figure 5F). To-
gether, these results suggest that SH2B3 could inhibit NGF-
induced signaling and neurite outgrowth through (1) interacting
with SH2B1b and sequestering it away from TrkA binding; and/
or (2) competing with SH2B1b for TrkA binding.
Carboxyl-termini but not amino-termini of SH2B3 is
required for inhibiting NGF-induced neurite initiation of
PC12 cells
To distinguish which mechanism accounts for the inhibitory
effect of SH2B3 on neurite outgrowth, amino (N)- and carboxyl
(C)-terminal truncation mutants were constructed. SH2B3(1–296)
contains DD, proline-rich and PH domains. SH2B3(296–575)
contains SH2 domain (Figure 6A). If SH2B3 acts to bind and
sequester SH2B1b away from binding to TrkA, expressing
SH2B3(1–296) should be sufficient to block NGF-induced neurite
Figure 2. NGF-induced neuronal differentiation of PC12 cells stably expressing GFP, GFP-SH2B1b or GFP-SH2B3, and SH2B3-
knockdown cells. (A) Cell lysates were extracted from PC12-GFP, PC12-SH2B1b or PC12-SH2B3 cells and analyzed via western blotting using anti-
GFP antibody. (B) PC12-GFP, PC12-SH2B1b or PC12-SH2B3 cells were treated without or with NGF 50 ng/ml for 4 days. Representative images of live
cells are shown. Scale bar: 50 mm. (C) Differentiation percentage of PC12-GFP, PC12-SH2B1b or PC12-SH2B3 cells treated with NGF 50 ng/ml for 4
days. The definition of differentiation is shown in the Materials and Methods. *: P,0.05, paired Student t-test. (D) PC12 cells were infected with
(shSH2B3) or without (Ctrl) lentivirus containing shSH2B3, followed by 50 ng/ml NGF treatment for 4 h. Relative mRNA of SH2B3 was analyzed using
Q-PCR. The relative SH2B3 levels were normalized to the levels of GADPH. *: P,0.05, paired Student t-test. (E) PC12 cells were infected with shSH2B3-
containing lentivirus (shSH2B3) or without (Ctrl), and then treated with 100 ng/ml NGF for 24 h. Percentages of differentiation were determined and
shown. *: P,0.05, paired Student t-test.
doi:10.1371/journal.pone.0026433.g002
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26433Figure 3. NGF-induced signaling in PC12-GFP, PC12-SH2B1b and PC12-SH2B3 cells. (A) PC12-GFP, PC12-SH2B1b and PC12-SH2B3 cells
were cultured in serum-free medium overnight before treating with 100 ng/ml NGF for the indicated time points. Cell lysates were collected and
analyzed via western blotting using anti-pPLCc, anti-PLCc, anti-pERK1/2, anti-ERK1/2, anti-phospho-Ser473 of AKT (pAkt), anti-AKT, anti-phospho-
Ser727 of STAT3 (pSTAT3) and anti-STAT3 antibodies. (B) The relative levels of pPLCc, pERK1/2, pAKT, or pSTAT3 were normalized to levels of PLCc,
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expressing SH2B3(296–575) shall inhibit neurite outgrowth. The
expression of these truncation mutants is shown in Figure 6B. To
determine their effect on neurite outgrowth, PC12 cells were
transiently transfected with GFP, GFP-SH2B3, GFP-SH2B3(1-
296), and GFP-SH2B3(296–575) followed by NGF treatment. In
control PC12-GFP cells, neurites were initiated within 2 days and
the length of neurites increased on Day 4. In line with the results
from Figures 2, 4 and 5, overexpression of SH2B3 inhibited
neurite outgrowth. Neurite initiation (Day 2) was not affected by
overexpression of SH2B3(1–296) but neurite elongation (Day 4)
appeared to be impaired. Overexpression of SH2B3(296–575), on
the other hand, inhibited neurite initiation (Figure 6C). The
averaged length of neurites for cells transfected with GFP or GFP-
SH2B3(1–296) was 75 mm on Day 2 of NGF treatment whereas
the length of neurites increased to 120 mm for GFP-transfected
cells, and the length of neurites for GFP-SH2B3(1–296)-transfect-
ed cells did not increase (Figure 6D). These results suggest that the
SH2 domain of SH2B3 is responsible for the main inhibitory effect
of SH2B3 on neurite initiation. In other words, SH2B3 likely
competes with SH2B1b for TrkA binding. If this is true, one would
expect the dominant negative mutant of SH2B3 that does not bind
to receptor tyrosine kinase would not block neurite outgrowth.
R392E mutation in the SH2 domain of SH2B3 prevents its
binding to c-Kit [19]. To this end, PC12 cells were transiently
transfected with GFP, GFP-SH2B3, or GFP-SH2B3(R392E), as
shown in Figure 7A. Cells expressing GFP or GFP-SH2B3(R392E)
exhibited neurites after 2 days of NGF treatment. In contrast, cells
expressing SH2B3 inhibited neurite initiation (Figure 7A). Simi-
larly, around 11% of cells expressing GFP or GFP-SH2B3(R392E)
were differentiated whereas cells expressing SH2B3 inhibited
neuronal differentiation (Figure 7B). Overexpression of SH2B3 in
PC12-SH2B1b cells interfered with SH2B1b-enhanced neurite
outgrowth whereas overexpression of SH2B3(R392E) did not
(Figure 7C). Percentage of neurite-bearing cells for PC12-SH2B1b
cells was 70%. When SH2B3 was co-expressed, the percentage
was reduced to around 30% whereas overexpression SH2B3
(R392E) did not significantly change the percentage (Figure 7D).
These results further support the mechanism that SH2B3 inhibits
NGF signaling and neurite outgrowth through binding to TrkA,
reduced TrkA phosphorylation, and reduced the interaction
between SH2B1b and TrkA.
ERK1/2, AKT and STAT3 from three independent experiments. *: P,0.05, paired Student t-test. (C) PC12-GFP, PC12-SH2B1b and PC12-SH2B3 cells
were treated with 100 ng/ml of NGF for 0, 0.5 or 1 h. Cell lysates were subjected to western blot analysis using anti-Egr-1 or anti-tubulin antibody.
Tubulin levels serve as loading controls. (D) The relative levels of 1 h NGF-induced Egr-1 from three independent experiments were normalized to
those for PC12-GFP cells (=1). *: P,0.05, paired Student t-test.
doi:10.1371/journal.pone.0026433.g003
Figure 4. Overexpressing SH2B3 inhibits FGF1-induced signaling and neuronal differentiation of PC12 cells. (A) PC12, PC12-SH2B1b
and PC12-SH2B3 cells were treated with 100 ng/ml of FGF1 together with 10 mg/ml of heparin for 6 days. Representative images of live cells are
shown. Scale bar: 50 mm. (B) PC12 cells were treated as in (A), differentiation rate of PC12, PC12-SH2B1b, or PC12-SH2B3 cells on Day 6 was analyzed
as described in the Materials and Methods from three independent experiments. *: P,0.05, paired Student t-test. (C) PC12-GFP, PC12-SH2B1b and
PC12-SH2B3 cells were treated with 100 ng/ml of FGF1 together with 10 mg/ml of heparin for 0, 5, or 10 min. Cell lysates were collected, analyzed via
western blotting using anti-pERK1/2 and anti-ERK1/2 antibodies. (D) PC12-GFP, PC12-SH2B1b and PC12-SH2B3 cells were treated with 100 ng/ml of
FGF1 together with 10 mg/ml of heparin for 0, 0.5, or 1 h. Cell lysates were analyzed via western blotting using anti-Egr-1 and anti-tubulin antibodies.
Tubulin levels serve as loading controls.
doi:10.1371/journal.pone.0026433.g004
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We next determine whether SH2B3 also exerts inhibitory effect
on the development of cortical neurons. Cortical neurons were
isolated from E18 embryo, GFP, GFP-SH2B3, GFP-SH2B3(1–
296), or GFP-SH2B3(296–575) was transiently transfected to DIV
4 neurons. Dendrites as well as axonal growth were monitored
each day. Live cell images shown are from DIV 5. Neurons
transfected with GFP showed normal dendrite morphology with
one longest neurite being the axon. When GFP-SH2B3 was
overexpressed, most neurites appeared as dendrite-like morphol-
Figure 5. Overexpression of SH2B3 interferes with the interaction between SH2B1b and TrkA. (A) PC12 cells were transfected with myc-
SH2B1b, myc-SH2B1b(R555E), or GFP-SH2B3. Cell lysate was immunoprecipitated using anti-myc antibody and immunoblotted with anti-myc and
anti-GFP antibodies. Lower panels are cell lysate controls. (B) 293T cells were transfected with pCMV5-TrkA, and co-expressed with myc vector, myc-
SH2B1b, myc-SH2B3, or myc-SH2B3(R392E) followed by 100 ng/ml NGF treatment for 15 min. Cell lysates were immunoprecipitated using anti-myc
antibody and immunoblotted with anti-myc and anti-TrkA antibodies. Lower panels are cell lysate controls. (C) 293T cells were treated as in (B), cell
lysates were immunoprecipitated using anti-TrkA antibody and immunoblotted with anti-TrkA and anti-myc antibodies. Lower panels are cell lysate
controls. (D) 293T cells were transfected with pCMV5-TrkA, myc-SH2B1b and/or GFP-SH2B3 followed by 100 ng/ml NGF treatment for 15 min. Cell
lysates were immunoprecipitated using anti-myc antibody and immunoblotted with anti-TrkA and anti-myc antibodies. Lysate blots were
immunoblotted with anti-myc, anti-TrkA, anti-phospho-tyrosine 490 of TrkA [pTrkA(Y490)], and anti-GFP antibodies (lower panels). (E) PC12-SH2B1b
cells were transiently transfected with myc vector or myc-SH2B3. Cells were then treated with 100 ng/ml of NGF for 24 h and then subjected to
immunofluorescence staining using anti-myc antibody and Alexa Fluor 555-conjugated secondary antibody (red). Green fluorescence represents GFP-
SH2B1b. Images were taken using Zeiss Observer Z1. Scale bar: 50 mm. (F) PC12-SH2B1b cells were treated as in (E), percentages of differentiation for
myc-positive cells on were analyzed as described in the Materials and Methods from three independent experiments. *: P,0.05, paired Student t-test.
doi:10.1371/journal.pone.0026433.g005
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isolated and cultured in vitro, neurites are initiated spontaneously.
So, one cannot test the effect of SH2B3 on neurite initiation.
Similar to the results shown for PC12 cells, neurite elongation,
specifically the axonal extension, was inhibited for cortical neurons
that overexpressed GFP-SH2B3(1–296) (Figure 8B). Axonal
marker, Tau-1, was used to identify axons. Neurons that
overexpressed SH2B3(296–575) did not block axonal growth
consistent with its role in affecting neurite initiation in PC12 cells
(Figure 8A–B). The averaged axonal length of cortical neurons was
Figure 6. Carboxyl-terminal region of SH2B3 is sufficient to inhibit NGF-induced neurite initiation of PC12 cells. (A) Schematic
representation of full-length and truncated human SH2B3 proteins. P represents proline-rich domain. (B) PC12 cells were transiently transfected with
GFP, GFP-SH2B3, GFP-SH2B3(1–296), or GFP-SH2B3(296–575). Cells lysates were analyzed via western blotting using anti-GFP antibody. * indicates the
overexpressed GFP-fusion proteins. (C) PC12 cells were transiently transfected with GFP, GFP-SH2B3, GFP-SH2B3(1–296), or GFP-SH2B3(296–575)
followed by the treatment of 100 ng/ml of NGF for 2 or 4 days. Representative images of live cells were shown. Scale bar: 50 mm. (D) PC12 cells were
treated as in (C), the averaged neurite length on Day 2 and 4 was measured from three independent experiments. Total numbers of cells counted are
shown on the bars. *: P,0.05, one-way ANOVA.
doi:10.1371/journal.pone.0026433.g006
Figure 7. SH2 domain of SH2B3 is required for inhibiting neuronal differentiation in PC12 cells. PC12 cells were transiently transfected
with GFP, GFP-SH2B3, or GFP-SH2B3(R392E) and then treated with 100 ng/ml of NGF for 2 days. Representative images of live cells are shown. Scale
bar: 50 mm. (B) PC12 cells were treated as in (A), differentiation rate of GFP-, GFP-SH2B3, or GFP-SH2B3(R392E)-expressing cells on Day 2 was analyzed
as described in the Materials and Methods from three independent experiments. *: P,0.05. (C) PC12-SH2B1b cells were transiently transfected with
myc vector (upper panels), myc-SH2B3 (middle panels), or myc-SH2B3(R392E) (lower panels). Cells were then treated with 100 ng/ml of NGF for 24 h
followed by immunofluorescence staining using anti-myc antibody and Alexa Fluor 555-conjugated secondary antibody (red). Green fluorescence
represents GFP-SH2B1b. Images were taken using Zeiss Observer Z1. Scale bar: 50 mm. (D) PC12-SH2B1b cells were treated as in (C), percentages of
myc-positive cells that have neurites were determined from three independent experiments. *: P,0.05, paired Student t-test.
doi:10.1371/journal.pone.0026433.g007
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expressing SH2B3 and SH2B3(1–296) and 250 mm for those that
expressed SH2B3(296–575) (Figure 8C).
Taken together, this study presents the first characterization of
the role of SH2B3 on neurite outgrowth of PC12 cells and cortical
neurons. Unlike SH2B1b in enhancing neurotrophic factors-
induced neurite outgrowth, overexpression of SH2B3 blocked it.
Overexpressing SH2B3 significantly reduced NGF- and FGF1-
induced signaling. We further demonstrated that the binding of
SH2B3 to TrkA was required for the inhibitory effect. An
interesting finding from this work suggests that the amino acids 1–
296 of SH2B3 inhibit axonal elongation, whereas amino acids
296–575 inhibit neurite initiation.
Discussion
In this study, we demonstrated that SH2B3 was expressed in the
cerebral cortex of embryonic rat brain. In PC12 cells, the
expression of SH2B3 was increased in response to NGF
stimulation. However, overexpression of SH2B3 inhibited NGF-
induced neurite outgrowth suggesting a novel function of SH2B3
in desensitizing NGF signaling. This result makes SH2B3 the only
member of SH2B adaptor family capable of exerting a negative
role on NGF signaling and neurite outgrowth. To understand the
mechanism by which SH2B3 may exert its inhibitory effect, we
showed that SH2B3 bound to activated TrkA. However,
overexpressing SH2B3 reduced NGF-indcued pTrkA(Y490),
reduced the interaction between SH2B1b and TrkA, and thus
reduced NGF signaling and neurite outgrowth. Theses findings
put SH2B3 as a feedback-induced antagonist of NGF- and FGF1-
induced signaling, similar to Sprouty, Sef (similar expression to
FGF) and Spred families [29,30,31,32,33,34].
SH2B3 has previously been shown to negatively regulate
signaling initiated by Epo receptor, interleukin-3 receptor, c-Kit,
and Mpl [19,21,35,36]. Given the various domains within SH2B3,
it could potentially modulate downstream signaling in diverse
ways. Results from the current study implicated that SH2B3
reduced the phosphorylation of TrkA at tyrosine 490 as well as the
interaction between SH2B1 and TrkA. Phosphorylation of TrkA
at tyrosine 490 recruits another adaptor Shc [8]. This result
strongly implicates that overexpression of SH2B3 reduces the
recruitment of Shc to TrkA-containing complexes. It is also
possible that overexpression of SH2B3 may reduce the overall
phosphorylation of TrkA. Phosphorylation of TrkA may contrib-
ute to the stability of dimerized TrkA allowing for the recruitment
of other signaling proteins. Along this line, reduced binding of
TrkA and PLCc, as has been demonstrated for the inhibitory
effect of SH2B2 on platelet-derived growth factor receptor B
(PDGFRB) signaling [37]. SH2B3 could potentially regulate TrkA
stability. Although both human and rat SH2B3 contain a binding
site for c-Cbl, an ubiquitin ligase that functions to target proteins
for degradation [38], human and rat SH2B1b do not (Figure S1).
This difference may underlie the differential effect of hSH2B3 and
rSH2B1b in inhibiting versus enhancing NGF signaling. For
instance, in response to NGF, hSH2B3 may recruit c-Cbl to
ubiquitinate TrkA, reduce its levels and thus desensitizes NGF
signaling. Another possible mechanism is that SH2B3 negatively
regulates TrkA-containing complexes by recruiting a putative
phosphatase to de-phosphorylate pTrkA. This would then lead to
reduced interaction between SH2B1b and TrkA without directly
competing with SH2B1b for the same binding sites on TrkA.
SH2 domain is believed to interact with activated receptor
tyrosine kinases. Nevertheless, a very recent report suggests that
activation of PDGFRs is dispensable for the interaction with
SH2B3 [39]. The authors hypothesized that the domain of SH2B3
flanked by DD and PH domains (contains three proline-rich
regions) is responsible for phosphotyrosine-independent binding of
SH2B3 to PDGFRs [39]. Our results from this work cannot
exclude the possibility that SH2B3(1–296), containing DD,
proline-rich and PH domains, could bind to TrkA with low
Figure 8. SH2B3 inhibits neurite extension of cortical neurons. (A) Isolated E18 rat cortical neurons were transfected with GFP, GFP-SH2B3,
GFP-SH2B3(1–296), or GFP-SH2B3(296–575) on DIV 4. Images were taken on DIV 5. Scale bar: 50 mm. (B) E18 rat cortical neurons were treated as in (A).
Transfected neurons were shown on the upper panels. Cells were subjected to immunofluorescence staining using anti-Tau-1 antibody and Alexa
Fluor 555-conjugated secondary antibody (lower panels). Tau-1 is an axonal marker. Arrow points to GFP-SH2B3(296-575)-transfected cell. Images
were taken using Zeiss Observer Z1 microscope. Scale bar: 50 mm. (C) E18 rat cortical neurons were treated as in (A). The averaged neurite length on
DIV 5 was measured using Image J software. Total numbers of neurons analyzed are shown on the bars. *: P,0.05, one-way ANOVA.
doi:10.1371/journal.pone.0026433.g008
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ing SH2B3(1-296) did not block neurite initiation but blocked
neurite elongation of PC12 cells and axonal extension of cortical
neurons. Nonetheless, this result could also due to the inhibitory
effect caused by the NGF-induced SH2B3 levels. Another
possibility is that SH2B3(1–296) could dimerize with SH2B1
through DD domain, interfere with actin- and Rac-binding ability
of SH2B1 and thus inhibit actin remodeling during neurite
outgrowth. Amino acids 296-575 of SH2B3 on the other hand
inhibit specifically neurite initiation of PC12 cells. As cortical
neurons are isolated and cultured in vitro, neurites initiate
spontaneously. Thus, the inhibitory effect of neurite initiation of
cortical neurons by SH2B3(296–575) was not observed.
The main physiological outcome of suppressing growth factor or
cytokine signaling by SH2B3 is reduced proliferation [17,19,21].
During NGF-induced neuronal differentiation in PC12 cells,
increased proliferation at early phase is required [40]. Thus,
inhibiting proliferation by SH2B3 could well be another
mechanism of its inhibitory effect on neuronal differentiation.
During embryonic development, tightly regulated balance be-
tween proliferation and differentiation controls cell fate. We think
that different SH2B family members may serve to maintain this
fine balance to assure normal development.
Supporting Information
Figure S1 Sequence alignment of the SH2 domains of
rat SH2B1b and human SH2B3. Sequences of the SH2
domains of rat SH2B1b (rSH2B1beta) and human SH2B3
(hSH2B3) were aligned using NCBI protein blast function
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). *: exact match between
the two sequences. The recognition site for c-Cbl was marked.
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